Consensus on molecular imaging and theranostics in prostate cancer

Stefano Fanti, Silvia Minozzi, Gerald Antoch, Ian Banks, Alberto Briganti, Ignasi Carrio, Arturo Chiti, Noel Clarke, Matthias Eiber, Johann De Bono, Karim Fizazi, Silke Gillessen, Sam Gledhill, Uwe Haberkorn, Ken Herrmann, Rodney J Hicks, Frederic Lecouvet, Rodolfo Montironi, Piet Ost, Joe M O'SullivanAnwar R Padhani, Jack A Schalken, Howard I Scher, Bertrand Tombal, R Jeroen A van Moorselaar, Heindrik Van Poppel, Hebert Alberto Vargas, Jochen Walz, Wolfgang A Weber, Hans-Jürgen Wester, Wim J G Oyen

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Although the advances in MRI and PET-CT have improved the accuracy of imaging, the effects of these new methods on clinical outcomes remains to be established. Improved communication between imagers and clinicians and more multidisciplinary input in clinical trial design are essential to encourage imaging insights into clinical decision making.

Original languageEnglish
Pages (from-to)e696-e708
Number of pages13
JournalLancet Oncology
Volume19
Issue number12
Early online date28 Nov 2018
DOIs
Publication statusPublished - 01 Dec 2018

Fingerprint

Molecular Imaging
Prostatic Neoplasms
Consensus
Radiopharmaceuticals
Bone and Bones
Samarium
Guidelines
Rhenium
Radium
Sodium Fluoride
Strontium
Gallium
Survival
Fluorine
Nuclear Medicine
Diphosphonates
Palliative Care
Communication
Clinical Trials
Therapeutics

Bibliographical note

Copyright © 2018 Elsevier Ltd. All rights reserved.

Cite this

Fanti, S., Minozzi, S., Antoch, G., Banks, I., Briganti, A., Carrio, I., ... Oyen, W. J. G. (2018). Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, 19(12), e696-e708. https://doi.org/10.1016/S1470-2045(18)30604-1
Fanti, Stefano ; Minozzi, Silvia ; Antoch, Gerald ; Banks, Ian ; Briganti, Alberto ; Carrio, Ignasi ; Chiti, Arturo ; Clarke, Noel ; Eiber, Matthias ; De Bono, Johann ; Fizazi, Karim ; Gillessen, Silke ; Gledhill, Sam ; Haberkorn, Uwe ; Herrmann, Ken ; Hicks, Rodney J ; Lecouvet, Frederic ; Montironi, Rodolfo ; Ost, Piet ; O'Sullivan, Joe M ; Padhani, Anwar R ; Schalken, Jack A ; Scher, Howard I ; Tombal, Bertrand ; van Moorselaar, R Jeroen A ; Van Poppel, Heindrik ; Vargas, Hebert Alberto ; Walz, Jochen ; Weber, Wolfgang A ; Wester, Hans-Jürgen ; Oyen, Wim J G. / Consensus on molecular imaging and theranostics in prostate cancer. In: Lancet Oncology. 2018 ; Vol. 19, No. 12. pp. e696-e708.
@article{8fbfdb055f834ee5aa1ee9a9e2016171,
title = "Consensus on molecular imaging and theranostics in prostate cancer",
abstract = "Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Although the advances in MRI and PET-CT have improved the accuracy of imaging, the effects of these new methods on clinical outcomes remains to be established. Improved communication between imagers and clinicians and more multidisciplinary input in clinical trial design are essential to encourage imaging insights into clinical decision making.",
author = "Stefano Fanti and Silvia Minozzi and Gerald Antoch and Ian Banks and Alberto Briganti and Ignasi Carrio and Arturo Chiti and Noel Clarke and Matthias Eiber and {De Bono}, Johann and Karim Fizazi and Silke Gillessen and Sam Gledhill and Uwe Haberkorn and Ken Herrmann and Hicks, {Rodney J} and Frederic Lecouvet and Rodolfo Montironi and Piet Ost and O'Sullivan, {Joe M} and Padhani, {Anwar R} and Schalken, {Jack A} and Scher, {Howard I} and Bertrand Tombal and {van Moorselaar}, {R Jeroen A} and {Van Poppel}, Heindrik and Vargas, {Hebert Alberto} and Jochen Walz and Weber, {Wolfgang A} and Hans-J{\"u}rgen Wester and Oyen, {Wim J G}",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/S1470-2045(18)30604-1",
language = "English",
volume = "19",
pages = "e696--e708",
journal = "Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "12",

}

Fanti, S, Minozzi, S, Antoch, G, Banks, I, Briganti, A, Carrio, I, Chiti, A, Clarke, N, Eiber, M, De Bono, J, Fizazi, K, Gillessen, S, Gledhill, S, Haberkorn, U, Herrmann, K, Hicks, RJ, Lecouvet, F, Montironi, R, Ost, P, O'Sullivan, JM, Padhani, AR, Schalken, JA, Scher, HI, Tombal, B, van Moorselaar, RJA, Van Poppel, H, Vargas, HA, Walz, J, Weber, WA, Wester, H-J & Oyen, WJG 2018, 'Consensus on molecular imaging and theranostics in prostate cancer', Lancet Oncology, vol. 19, no. 12, pp. e696-e708. https://doi.org/10.1016/S1470-2045(18)30604-1

Consensus on molecular imaging and theranostics in prostate cancer. / Fanti, Stefano; Minozzi, Silvia; Antoch, Gerald; Banks, Ian; Briganti, Alberto; Carrio, Ignasi; Chiti, Arturo; Clarke, Noel; Eiber, Matthias; De Bono, Johann; Fizazi, Karim; Gillessen, Silke; Gledhill, Sam; Haberkorn, Uwe; Herrmann, Ken; Hicks, Rodney J; Lecouvet, Frederic; Montironi, Rodolfo; Ost, Piet; O'Sullivan, Joe M; Padhani, Anwar R; Schalken, Jack A; Scher, Howard I; Tombal, Bertrand; van Moorselaar, R Jeroen A; Van Poppel, Heindrik; Vargas, Hebert Alberto; Walz, Jochen; Weber, Wolfgang A; Wester, Hans-Jürgen; Oyen, Wim J G.

In: Lancet Oncology, Vol. 19, No. 12, 01.12.2018, p. e696-e708.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Consensus on molecular imaging and theranostics in prostate cancer

AU - Fanti, Stefano

AU - Minozzi, Silvia

AU - Antoch, Gerald

AU - Banks, Ian

AU - Briganti, Alberto

AU - Carrio, Ignasi

AU - Chiti, Arturo

AU - Clarke, Noel

AU - Eiber, Matthias

AU - De Bono, Johann

AU - Fizazi, Karim

AU - Gillessen, Silke

AU - Gledhill, Sam

AU - Haberkorn, Uwe

AU - Herrmann, Ken

AU - Hicks, Rodney J

AU - Lecouvet, Frederic

AU - Montironi, Rodolfo

AU - Ost, Piet

AU - O'Sullivan, Joe M

AU - Padhani, Anwar R

AU - Schalken, Jack A

AU - Scher, Howard I

AU - Tombal, Bertrand

AU - van Moorselaar, R Jeroen A

AU - Van Poppel, Heindrik

AU - Vargas, Hebert Alberto

AU - Walz, Jochen

AU - Weber, Wolfgang A

AU - Wester, Hans-Jürgen

AU - Oyen, Wim J G

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Although the advances in MRI and PET-CT have improved the accuracy of imaging, the effects of these new methods on clinical outcomes remains to be established. Improved communication between imagers and clinicians and more multidisciplinary input in clinical trial design are essential to encourage imaging insights into clinical decision making.

AB - Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Although the advances in MRI and PET-CT have improved the accuracy of imaging, the effects of these new methods on clinical outcomes remains to be established. Improved communication between imagers and clinicians and more multidisciplinary input in clinical trial design are essential to encourage imaging insights into clinical decision making.

U2 - 10.1016/S1470-2045(18)30604-1

DO - 10.1016/S1470-2045(18)30604-1

M3 - Review article

C2 - 30507436

VL - 19

SP - e696-e708

JO - Lancet Oncology

JF - Lancet Oncology

SN - 1470-2045

IS - 12

ER -

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I et al. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology. 2018 Dec 1;19(12):e696-e708. https://doi.org/10.1016/S1470-2045(18)30604-1